Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 10/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.33 |
| ▸ | LYN | P07948 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16248091 | 0.89 | BTK (0.41) | BTKPDE10AP2RX3 | |
| SCHEMBL10263468 | 0.88 | BTK (0.48) | BTKABL1PDE10ALYNSRC | |
| SCHEMBL610812 | 0.88 | BTK (0.39) | BTKPDE10ALYNSRC | |
| SCHEMBL609693 | 0.86 | BTK (0.42) | BTKPDE10A | |
| SCHEMBL14696705 | 0.86 | BTK (0.40) | BTKPDE10ALYNSRC | |
| SCHEMBL10201611 | 0.85 | PPARA (0.40) | BTKPDE10AP2RX3 | |
| SCHEMBL608994 | 0.84 | SYK (0.42) | BTKPDE10AP2RX3LYNSRC | |
| SCHEMBL609229 | 0.84 | BTK (0.37) | BTKPDE10AP2RX3SRC | |
| SCHEMBL10279193 | 0.83 | BTK (0.38) | BTKPDE10AP2RX3SRC | |
| SCHEMBL609575 | 0.83 | PPARA (0.46) | BTKP2RX3MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2964642-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2017-11-15 | — | — | EP | disclosed |
| EP-2964642-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2017-11-15 | — | — | EP | disclosed |
| US-9663494-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663494-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663494-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2017-05-30 | — | — | US | disclosed |
| EP-2744804-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2017-05-17 | — | — | EP | disclosed |
| EP-2744804-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2017-05-17 | — | — | EP | disclosed |
| EP-2964642-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. Hoffmann-La Roche AG (CH) | 2016-01-13 | — | — | EP | disclosed |
| US-20150376166-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150376166-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-20130045965-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. | 2013-02-21 | — | — | US | disclosed |
| US-20130045965-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. | 2013-02-21 | — | — | US | disclosed |
| WO-2013024078-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013024078-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-21 | — | — | WO | disclosed |
| US-20130045965-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. | 2013-02-21 | — | — | US | disclosed |
| WO-2012020008-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012020008-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | WO | disclosed |
| US-20120040949-A1 | Inhibitors of Bruton's Tyrosine Kinase | BERTHEL STEVEN JOSEPH (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040949-A1 | Inhibitors of Bruton's Tyrosine Kinase | BERTHEL STEVEN JOSEPH (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040949-A1 | Inhibitors of Bruton's Tyrosine Kinase | BERTHEL STEVEN JOSEPH (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376166-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | BTK 1/4885ABL1 12/4885PDE10A 597/4885 |
| US-20120040949-A1 | Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LYN | BTK 1/4885ABL1 27/4885PDE10A 867/4885 |
| US-20130045965-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | BTK 1/4885ABL1 12/4885PDE10A 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.